Ovid Therapeutics — Third Quarter 2026 Earnings Summary

Ovid Therapeutics reported a net loss of $20.8 million for the third quarter ended September 30, 2026, with cash, cash equivalents, and marketable securities totaling $161.4 million as of that date. The company is advancing its lead candidate OV329, a next-generation GABA-AT inhibitor, through a Phase 2 study for treatment-resistant focal epilepsy expected to conclude in the second half of 2027, alongside a photosensitivity study with results anticipated in early 2027. Additionally, OV4071, the first oral KCC2 direct activator, is progressing in a Phase 1 trial with topline data expected in the first quarter of 2027, while a pediatric formulation of OV329 is on track to initiate a study for TSC-associated seizures before the end of 2026.